ArticleBMC infectious diseases2026
Bacterial etiology, antimicrobial susceptibility, and clinical outcomes in cervicofacial space infections before, during, and after the COVID-19 pandemic: a 10-year single-centre study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate epidemiological trends of cervicofacial space infections in Western China, including pathogen distribution, antimicrobial resistance, and the impact of the COVID-19 pandemic on pathogen susceptibility and patient outcomes.
methodsClinical data from 542 hospitalized patients with severe cervicofacial space infections who underwent open surgery at a tertiary hospital over the past decade were analyzed. Data on bacterial strains, antibiotic susceptibility, drug resistance, and treatment outcomes were recorded. Statistical analyses included one-way ANOVA, chi-square tests, Fisher's exact tests, logistic regression, and multiple regression.
resultsFrom January 2014 to June 2024, the annual number of hospitalized CFI cases declined initially but later increased. Bacterial growth was observed in 400 cases (73.8%). Based on the frequency of isolation in positive pus cultures, Streptococcus spp. and Klebsiella spp. were the most frequently identified organisms. The five antimicrobial agents with the highest in vitro susceptibility rates were levofloxacin (66.3%), vancomycin (63.8%), cefepime (61.0%), ceftriaxone (59.5%), and cefotaxime (58.5%). Compared to the pre-pandemic period, Patients treated during the pandemic and post-pandemic periods had higher odds of in-hospital complications than those treated during the pre-pandemic period (OR = 7.28, 95% CI:3.67 ~ 14.45; P < 0.001; OR = 4.96, 95% CI:2.16 ~ 11.41; P < 0.001), including pulmonary infections, and coagulopathy etc.
conclusionsBased on the prevalent pathogen profile and local susceptibility patterns observed in this study, cephalosporins are the preferred empirical choice for cervicofacial space infections in our region. Fluoroquinolones may be considered as an alternative in patients with beta-lactam allergy, but should be used judiciously to preserve their activity for resistant organisms. Antibiotic therapy should be tailored based on culture and susceptibility results as soon as they become available. Additionally, patients treated during and after the COVID-19 pandemic had higher odds of in-hospital complications, which may reflect healthcare system disruptions and delayed presentation. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.